[HTML][HTML] Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer
JJ Lin, VW Zhu, S Yoda, BY Yeap… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.gov
Purpose Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs).
However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a
result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect
clinical outcome, but the molecular basis for this association is unknown.
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs).
However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a
result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect
clinical outcome, but the molecular basis for this association is unknown.
Abstract
Purpose
Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis for this association is unknown.
ncbi.nlm.nih.gov